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Abstract
Background: The Affordable Care Act (ACA) required private insurers and Medicare to cover recommended
preventive services without any cost sharing to improve utilization of these services. This study is an attempt to
identify the impact of removing cost sharing on mammography and pap test utilization rates.
Methods: Counterfactual analysis was used to predict what would have been the screening rates in post-ACA if
ACA was not there. This was done by estimating a model that examines determinants of dependent variable for
the pre-ACA year (pre-ACA year is 2009). The estimated model was then used to predict the dependent variable for
the post-ACA year using individual characteristics and other relevant variables unlikely to be affected by ACA (post-
ACA year is 2016). Effect of ACA is defined as the difference between the values of dependent variables in post-
ACA and the predicted values of dependent variables in the post-ACA year using counterfactual.
Results: The counterfactual analysis show that the utilization of mammogram and pap test did not improve
following ACA.
Conclusion: Removal of cost-sharing under the ACA did not improve mammography or pap test rates. Therefore,
financial barrier may not be an important factor in affecting utilization of the screening tests and policy makers
should focus on other non-financial barriers in order to improve coverage of the tests.
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Background
Cancer is among the leading causes of death in the
United States. An estimated 41,400 deaths from invasive
breast cancer and 4170 deaths from cervical cancer will
occur in 2018 [1]. Mammography and pap test screen-
ings allow early detection of the diseases leading to po-
tentially successful treatment [2–8]. Despite evidence of
screening effectiveness in improving health outcomes,
rates of mammography and pap test screenings
remained suboptimal in the United States [9]. The US
Preventive Services Task Force (USPSTF) recommends
mammography for women aged 50–74 years every two
years, and pap test for women aged 21–65 years every
three years [10]. According to the Centers for Disease
Control and Prevention (CDC), in 2015, 65.3% of
women aged 40 years and older had a mammogram
within previous two years, while 69% of women aged 18
years had a pap test within three years [9]. Subopti-
mal rates of screenings may have resulted from finan-
cial barriers women face such as cost-sharing, the
amount of money individuals required to pay when
seeking medical care. There is evidence that
cost-sharing reduces the use of health services, par-
ticularly preventive services [11, 12].
The Patient Protection and Affordable Care Act
(ACA) required private insurers and Medicare to cover
the USPSTF recommended preventive services with a
rating of A (strongly recommended) or B (recom-
mended) without any cost sharing. The policy became
effective on September 23, 2010 for private health in-
surers and on January 2011 for Medicare [13]. The goal
was to increase the use of preventive services and, in
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turn, reduce costly events from poorly or unmanaged
chronic conditions. Previous research reported mixed re-
sults regarding the impact of removing cost sharing on
mammography and pap test utilization [14–23]. As the
effect of removing cost-sharing on mammography and
pap test utilization are still unclear, this study aims to
generate evidence on the impact of changes brought
about by the ACA on mammography and pap tests
rates.
Methods
Outcome (dependent variable)
The study outcomes are the self-reported receipt of
mammogram and Pap test as measured in the Medical
Expenditure Panel Survey (MEPS) dataset. For each pre-
ventive service, respondents were asked “About how
long has it been since you had this mammogram/Pap
test?” with possible responses being “within past year,”
“within past 2 years,” etc. In accordance with screening
guidelines, a dummy variable was created for mammo-
gram utilization equal to 1 if the test was taken within 1
to 2 years, and a dummy variable for pap test utilization
equals to 1 if the test was taken within 1 to 3 years.
Design
We used a counterfactual analysis to determine the im-
pact of ACA on the preventive screenings rate. Counter-
factual analysis helps to understand what would have
happened in post-ACA year if ACA was not there. This
was done by estimating a model that examines determi-
nants of the dependent variable for pre-ACA (year
2009). Then, the estimated model was used to predict
the dependent variable using post-ACA characteristics
of individuals (the determinants from the model) (year
2016). The model basically works as pseudo control
group allowing estimation of the utilization of screenings
if ACA policy changes were absent. Effect of ACA is
then estimated as: rate of dependent variable post-ACA
minus the predicted rate of dependent variable in the
same post-ACA year using counterfactual (that there
was no ACA in that year). We chose determinants that
we believe may modify the demand for the screening
tests and the potential variables incorporated in the
model are: age, race, income, education, marital status,
region, health insurance type, physical activity, smoking
status, comorbidity, routine medical checkup, metropol-
itan area, out-of-pocket expenses, and the availability of
a usual source of care.
It is important to note that there are few determinants
of cancer screenings that are likely to change due to the
introduction of ACA, implying that incorporating these
variables for the post-ACA sample to define the counter-
factual will underestimate the effect of ACA. This is be-
cause the determinants affected by ACA will pick-up
some of the changes happened due to the implementa-
tion of ACA. Most important variables likely to change
due to the implementation of ACA are coverage rate of
health insurance and types of insurance people have. To
ensure that the counterfactual estimates are not biased,
insurance type and coverage rates were kept the same in
the post-ACA year as it was in the pre-ACA year. This
was done through adjusting the sampling weights so that
pre- and post-ACA insurance coverage and types of in-
surance coverage are the same. The dollar value of the
out-of-pocket variable was adjusted for inflation using
MCPI with 2016 as the base year.
Data
Data for this study was obtained from the Medical Ex-
penditure Panel Survey - Household Component
MEPS-HC [24]. The MEPS-HC is a set of large-scale sur-
veys designed and financed by the U.S. federal government
to address national questions regarding health care access,
utilization, and expenditure in the U.S. It collects data
from a sample of families and individuals in selected com-
munities across the United States, drawn from a nationally
representative subsample of households that participated
in the prior year’s National Health Interview Survey (con-
ducted by the National Center for Health Statistics). Dur-
ing the household interviews, MEPS collects detailed
information for each person in the household including
health care utilization, health insurance status, coverage
source, and out-of-pocket costs. Because the MEPS is the
most complete source of data on health care cost, use of
health care, and health insurance coverage in the United
States, it has been used extensively in scientific publica-
tions and published reports, as well as by the Federal and
State governments, to examine the delivery and financing
of health care in the United States. The combined average
response rate for the years 2009 and 2016 was 51.6% [25].
We obtained permission to access the restricted Area Re-
source File (ARF) that contained a “State” variable from
the Agency for Healthcare Research and Quality (AHRQ)
which was merged with the publicly available MEPS data-
set used in this study. The study was reviewed and ap-
proved by the Office of Research Compliance, an
administrative office that supports the University of South
Carolina Institutional Review Board (USC IRB). All data
used was fully anonymized before it was accessed.
Sample
Figure 1 shows the inclusion and exclusion criteria for
the study samples. From the MEPS 2009 and 2016 data
set, two separate cohorts are prepared to study utilization
of mammography and pap test. In accordance with the
USPSTF screening guidelines, the mammography cohort
includes women aged 40 and older and the pap test cohort
includes women aged 21–65. Although the recent
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USPSTF guidelines regarding breast cancer recommends
mammography for women aged 50–74 every 2 years, our
mammography cohort included women aged 40 and older
because the ACA still utilizes the 2002 guidelines. Women
with concurrent or past diagnoses with breast or cervical
cancer were excluded from the analysis to focus the ana-
lysis on screening for preventive purposes (Fig. 1).
Statistical analysis
Univariate analyses were done to produce descriptive
statistics of women’s characteristics before and after the
implementation of ACA in the sample. The main statis-
tical modeling is based on a regression equation explain-
ing the variability of the dependent variables in pre-ACA
period using a number of determinants or explanatory
variables. The equations estimated can be written as:
Yi0 = β0 + ∑ βjXij0, where Yio is the value of dependent
variable for individual i for the pre-ACA year 0 and [Xj]
is a set of potential determinants of Y. This estimated
model was then used to predict the dependent variable
for the post-ACA years using the values of determinants
in the post-ACA data set. In other words, we have pre-
dicted the values of Y for the post-ACA year t using the
estimates of β from the pre-ACA year.
Y it ¼ bβ0 þ
X
bβ jXijt
Another regression model was estimated to predict the
values of Y in post-ACA year using post-ACA data. The
effect of ACA would be the value of dependent variable
in the post-ACA year minus the predicted value of the
dependent variable in the post-ACA year using the re-
gression model obtained using pre-ACA year (the coun-
terfactual). A positive difference means that women in
post-ACA used more mammography and pap tests com-
pared to pre-ACA year given various determinants of
the dependent variable. Since a number of potential de-
terminants of dependent variable may be affected by the
ACA-triggered changes, these variables should be kept
constant at the pre-ACA level to obtain the true effect
of ACA. These variables are related with insurance
coverage and types of insurance under which the indi-
viduals are covered. We have kept the values of these
determinants constant in relative terms at the pre-ACA
level by changing the sampling weights proportionately.
To assess the diagnostic/predictive accuracy of our logis-
tic model, we used the area under the ROC curve
measure.
To better understand the estimated effects of ACA, we
regressed the difference of the dependent variables on
some population characteristics to examine how differ-
ent individual characteristics affect the outcomes. Differ-
ences were considered statistically significant if P-value
of the t-statistics < 0.05. All statistical analyses were car-
ried out using STATA software version 14 (2015; Stata
14.0 Statistical Software, College Station, TX, USA The
analyses accounted for probability weighting in the
MEPS [26, 27].
Results
Table 1 shows descriptive statistics of the women’s char-
acteristics in pre and post ACA. Women in pre-ACA
and post-ACA seem to have similar distribution demo-
graphic characteristics including age, income, education,
race, and insurance status, and the availability of usual
source of care (Table 1). Figure 2 shows the results from
the area under the ROC curve measure for our estima-
tion models which indicate that both estimating models
had an area under the curve was above 74%. Tables 2
shows the counterfactual analysis results which found
that the utilization of mammogram and pap test did not
increase following the ACA. Women in post-ACA used
less mammography and pap tests than the same period
post-ACA counterfactual (Table 2). The difference for
mammography is − 2.31 and for pap test is − 5.65 (Table
2). Tables 3 and 4 breaks down those differences by age,
race, income, education, and health insurance type. A
positive difference indicates that this particular group
decreases the difference while a negative difference indi-
cate that this particular group increases the difference.
For most categories, the difference was negative except
for women aged 50–64 and women with public insur-
ance implying that women aged 50–64 or with public
Fig. 1 Inclusion and exclusion criteria flow chart
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insurance used higher level of mammogram and pap
tests in post-ACA compared to the pre-ACA levels
(Table 3). Similarly, women used less pap tests in all
sub-groups in post-ACA year compared to the level in
counterfactual estimates (Table 4). Table 5 shows that
difference in probabilities are statistically significant.
Discussion
Because cost-sharing was found to reduce the use of
medical care services, particularly preventive care ser-
vices, the ACA required private health insurers and
Medicaid to cover preventive screenings recommended
by the USPSTF without cost-sharing. This study used a
counterfactual analysis to try to understand if the ACA’s
cost-sharing provisions impacted mammograms and Pap
tests rates.
In the years preceding the ACA, both mammogram
and Pap test coverage rates showed declining trends
among women in the U.S. [9]. Our results show that the
introduction of free preventive services did not affect
the overall declines in mammograms and Pap tests.
These results are consistent with previous studies that
found little impact of cost-sharing provision on mam-
mography and pap tests rates. For example, Hong et al.
[23] found decreased rates of being up-to-date on mam-
mograms and Pap tests among those with private insur-
ance after the ACA. Several other studies examined the
initial impact of removing cost-sharing on privately in-
sured women and found no change in mammography
and pap test [17–19]. Our results show no impact on
mammography use among women with Medicare (Table
3). Previous studies that looked at Medicare population
obtained mixed results regarding mammography
utilization after the ACA. For example, Jensen et al. [21]
found minimal change in mammography use among
older women, while other studies found statistically sig-
nificant increase in mammography uptake after the ACA
[14, 15]. Our analysis shows positive results in mammo-
gram rates for women aged 50–64 (Table 3). This is con-
sistent with a previous study that assessed the policy
from a health system level and found that ACA provi-
sions were associated with increased screening volumes
among 50–74 year old women [22]. There is evidence
that mammogram decrease breast cancer mortality
among women aged 50–69 but the benefit of mammog-
raphy for women aged 40–49 years is uncertain [28, 29].
Our results show that younger women used more Pap
Fig. 2 Area under the ROC curve for the estimating models
Table 1 Descriptive statistics of the characteristics of women
aged > = 21 in pre-ACA (2009) and post-ACA (2016), MEPS
database (Results)
Characteristics Pre-ACA
n = 13,146
Post-ACA
n = 12,786
% %
Age Mean 47 48
Race White 68 68
Black 21 20
Other 9 11
Education Some school 21 19
High School 31 29
College 47 50
Income Low 42 42
Middle 29 27
High 27 29
Insurance Private 57 57
Public 24 30
Uninsured 18 11
Usual source of care Available 77 77
Not available 22 22
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tests than older women (Table 4). This is consistent with
the guidelines and the evidence suggesting benefits from
Pap tests are more evident for younger women [30].
Our results show that black women had the lowest de-
cline in mammography and women from other minor-
ities had the lowest decline in Pap test use compared to
white women (Table 3 and Table 4). A recent study
found the ACA provision to be associated with im-
proved mammography and pap tests among Hispanics
and African Americans [31]. Looking at overall
utilization, black women had the highest rate of mam-
mogram and pap tests use (mammogram: 81.48%, pap
tests: 74.73%) (Table 3 and Table 4). Evidences show that
black women in the U.S. are more likely to be diagnosed
and die from breast and cervical cancer than the white
women, which may explain the increased use of screen-
ings among this group [32, 33].
There are some possible explanations for the little im-
pact of the ACA cost-sharing provision on slowing or re-
versing the declining rates of mammography and pap
tests. First, it is important to recognize that ACA’s
provision of no cost-sharing for preventive services was
found to be effective in improving coverage of a number
of preventive services such as blood pressure check,
cholesterol check, and flu vaccination, but it had no ef-
fect on cancer screenings. This is probably because the
guidelines for mammograms and Pap tests were updated
around the time of the ACA’s provisions. The guidelines
for mammograms were updated in 2009 to recommend
mammograms for women aged 50–75 every 2 years up-
dating the previous guidelines that recommended
screening every 1–2 years for women aged 40 and older.
The guidelines for cervical cancer screenings was up-
dated in 2012 to recommend the Pap test for women
aged 21–65 every three years updating the previous
guideline of screening annually for women who are
sexually active. These guideline updates, which recom-
mended reductions in the frequency of the tests, may
have led to overall declines in these cancer screenings.
In addition to the changing guidelines, some women
find the tests toxic or painful which may discourage
utilization [34–37]. Sometimes mammograms yield false
positive cases implying that some perfectly healthy
women will go through the pain, anxiety, and other side
Table 2 The difference in mammography and Pap tests use between post-ACA and post-ACA counterfactual (Results)
Post-ACA counterfactual
Predicting probabilities using 2009 model
Post-ACA
Predicting probabilities using 2016 model
Difference
Mammogram 71.67% 69.36% −2.31
Pap test 79.42% 73.77% −5.65
Table 3 The difference in mammography use between post-ACA and post-ACA counterfactual, by different population groups
(Results)
Category Post-ACA counterfactual
Predicting probabilities using 2009 model
Post-ACA
Predicting probabilities using 2016 model
Difference
Low income 62.29% 60.62% −1.67
Middle income 71.15% 69.82% −1.33
High income 82.40% 78.56% −3.84
Some school 60.61% 57.23% −3.38
High school 68.31% 68.08% −0.23
College 78.33% 75.21% −3.12
White 70.56% 68.46% −2.1
Black 76.24% 74.73% −1.51
Other 70.73% 65.57% −5.16
40–49 65.50% 60.96% −4.54
50–64 74.98% 75.52% + 0.54
> = 65 72.49% 69.38% −3.11
Private insurance 77.70% 74.92% −2.78
Public insurance 66.64% 66.70% + 0.06
Uninsured 42.75% 39.50% −3.25
Usual Source of Care available 76.03% 72.82% −3.21
Usual Source of Care not available 45.33% 49.96% −4.63
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effects because of the treatment. Similar to mammo-
grams, Pap tests may come with harm when abnormal
results lead to vaginal bleeding, pain, infection, and anx-
iety. Physicians make trade-offs between benefits and
risks when making recommendations about who should
be screened.
The second reason for little or no impact of ACA
provision could be that mammography and Pap tests
were covered with no or minimum cost-sharing by some
private insurance plans under Medicare Advantage even
before the introduction of ACA. The amount of
cost-sharing under Medicare was relatively small anyway
prior to ACA (20% cost sharing) and the new ACA
provision may not have affected out-of-pocket expenses
significantly. Another possibility is that some women
obtained screenings through national programs like
CDC’s National Breast and Cervical Cancer Early De-
tection Program (BCCEDP) in both pre- and
post-ACA years. The program was established in
1990 to provide free and/or reduced cost mammo-
grams and pap test to women with limited incomes
and those who lacked health insurance. The program
continued to provide large number of screenings in
the years following the ACA [38]. Any change in the
coverage of the program between pre- and post-ACA
years may show up as lack of effect of ACA unless
screenings done through these programs are con-
trolled for. Unfortunately, due to lack of data, it was
not possible to exclude women who obtained the can-
cer screenings through the BCCEDP.
In the years before the ACA, low-income women were
less likely to receive lifesaving recommended cancer
screenings [39]. A new study found that the ACA was
associated with improvements in health care-related fi-
nancial strain [40]. However, socioeconomic disparities
remained in term of mammograms and Pap tests
utilization. In our cohort, the majority of screenings oc-
curred among the high-income high-educated women
(Table 3 and Table 4). This is probably due to better
health literacy, awareness, and availability of time and
transportation. Our analysis show that the proportion of
women who reported having a usual source of care used
more mammogram and Pap tests than those with no
usual source of care (Table 3 and Table 4). Therefore,
factors related to provider availability and access may be
more effective in improving utilization rates.
Finally, it is important to recognize that, although
screening numbers did not improve following the ACA,
disease burden from breast and cervical cancer has been
declining over the years. Breast cancer rates have been
declining steadily in the past decade. Cervical cancer
cases have declined rapidly as well in past 40 years due
to wide use of Pap tests. Declines in cervical cancer
cases, however, have slowed down in recent years.
Conclusion
The rates of mammograms and Pap tests were already in
a declining trend in the years before the ACA and the
introduction of ACA provision of no cost-sharing did
not help change the declining trend. The rationale
Table 4 The difference in Pap tests use between post-ACA and post-ACA counterfactual, by different population groups (Results)
Category Post-ACA counterfactual
Predicting probabilities using 2009 model
Post-ACA
Predicting probabilities using 2016 model
Difference
Low income 76.24% 70.22% −6.05
Middle income 78.52% 72.68% −5.84
High income 84.85% 79.92% −4.93
Some school 70.46% 66.56% −3.9
High school 75.76% 69.22% −6.54
College 84.94% 79.14% −5.8
White 78.16% 71.62% −6.54
Black 85.32% 81.48% −3.84
Other 76.71% 73.46% −3.25
21–39 89.26% 86.17% −3.09
40–49 86.04% 84.51% −1.53
50–64 78.29% 73.74% −4.55
Private insurance 83.52% 79.09% −4.43
Public insurance 73.89% 65.44% −8.45
Uninsured 73.13% 68.96% −4.17
Usual Source of Care available 86.84% 83.77% −3.07
Usual Source of Care not available 79.18% 75.47% −3.71
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behind the ACA was built on the notion that
cost-sharing hinders the use of preventive care services.
Several post-ACA studies found positive impact of the
ACA on improving certain kinds of preventive care ser-
vices but not cancer screenings. Absence of positive ef-
fects of ACA on cancer screenings is possibly due to the
changes in guidelines for mammograms and Pap tests
and/or due to the fear of side effects from these screen-
ings. Although the overall screenings declined following
the ACA, declines were the lowest among women from
minority groups for Pap tests and the lowest among
black women for mammograms which indicate reducing
screening disparities by race. In addition, mammograms
rates improved among women aged 50–64 – the age
group most likely to benefit from the screening. Finally,
the results indicate – consistent with previous studies -
that the higher level of utilization rates are observed
among the wealthiest and most educated women even
after the services became free after the policy change. It
appears that financial barrier was not the most import-
ant factor in affecting utilization of these screening tests.
Therefore, policy makers should focus efforts on facili-
tating access, health promotion, and awareness which
may help improve screening rates. Future research is
recommended to look at possible factors affecting access
to care, provider availability and characteristics, phys-
ician compliance to guidelines to better understand the
reasons for lack of effects of cost reductions on
utilization of cancer screenings.
We acknowledge several limitations of this study. First,
information about outcomes relied on self-reported
survey responses which might be subject to recall
error. However, the MEPS follow up with health pro-
viders to reduce measurement errors but some errors
may remain, especially for procedures and tests re-
quiring longer recall. Second, the data used in the
analysis are cross-sectional and comparison of
cross-sectional data of different years is not same as
observing changes in the outcomes of the same set of
individuals over the years with the implementation of
the ACA. The study design made an attempt to
tease-out the effect of policy changes. Third, a longer
time frame may be needed to be able to see the ef-
fects of the policy changes on these outcomes.
Fourth, for the privately insured population, there is
no information on the coverage of screenings as
health plans that were grandfathered were not subject
to the ACA provision. Because the elimination of
cost-sharing is not universal for the privately insured,
full effect of removal of cost sharing will not be ob-
servable for this population group.
Another important factor for the lack of positive effect
of cost-sharing removal may be due to changes in the
USPSTF guidelines for breast cancer and cervical screen-
ing that occurred around the same time as the introduc-
tion of ACA provisions. The change in the guidelines
may have led to overall declines in cancer screening. In
2009 the guidelines for breast cancer screenings was up-
dated to recommend biennial screening instead of every
1–2 years. Also, in 2012 the USPSTF guidelines for cer-
vical cancer was updated to recommend the test every 3
years instead of every year. If the physicians start using
the new guidelines, mammogram and Pap test screen-
ings may appear lower if prior guideline based utilization
rates are calculated and compared. Counterfactual ana-
lysis will not be able to correct for the changes in
screening guidelines unless a control group can be iden-
tified for comparative purposes.
Table 5 Likelihood of the difference between post-ACA and
post-ACA counterfactual to increase/decrease explained by
different determinants (Results)
Category Difference in mammogram Difference in Pap test
Low income 0
(.)
0
(.)
Middle income 0.0256***
(37.05)
0.000804
(0.95)
High income −0.00406***
(−5.58)
0.0345***
(34.70)
Some school 0
(.)
0
(.)
High school 0.0298***
(37.44)
− 0.0204***
(−19.26)
College 0.0120***
(15.32)
−0.0280***
(−28.37)
White 0
(.)
0
(.)
Black −0.0196***
(−24.37)
0.0249***
(33.66)
Other −0.0386***
(−38.73)
0.0155***
(17.02)
21–39 0
(.)
40–49 0
(.)
0.00758***
(9.81)
50–64 0.0554***
(67.09)
−0.0303***
(−35.82)
> = 65 0.0284***
(32.22)
Private insurance 0
(.)
0
(.)
Public insurance 0.0285***
(42.36)
−0.0187***
(−20.24)
Uninsured −0.0279***
(−19.43)
− 0.0191***
(−13.70)
Cons_ − 0.0651***
(−36.92)
−0.0149***
(−8.80)
N 6364 8924
t statistics in parentheses * p < 0.05, ** p < 0.01, *** p < 0.001
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In any case, the analysis raises the concern that imple-
mentation of ACA’s cost share removal has not been ef-
fective in improving cancer screening rates and
longitudinal survey data would be needed to understand
why the removal of out of pocket costs failed to show the
intended effects. Unfortunately, the data we have are re-
peated cross-sectional. Longitudinal data covering a
period of four to five years are not available to conduct an
analysis to find out how the utilization of cancer screening
tests changed for the same individual over the years.
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